-
1.发明公开
公开(公告)号：EP1613658A2
公开(公告)日：2006-01-11
申请号：EP04725024.6
申请日：2004-04-01
发明人： GRAUS, Yvo , KOPETZKI, Erhard , KUENKELE, Klaus-Peter , MUNDIGL, Olaf , PARREN, Paul , REBERS, Frank , SCHUMACHER, Ralf , VAN DE WINKEL, Jan , VAN VUGT, Martine
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565
摘要： An antibody binding to IGF-IR and inhibiting the binding of IGF-I and IGF-II to IG-RI which is characterized in that said antibody is of human IgG1 isotype, and shows a ratio of inhibition of the binding of IGF-I to IGF-IR to the inhibition of binding of IGF-II to IGF-IR of 1:3 to 3:1, and induces celle death of 20% or more cells of a preparation of IGF-IR expressing cells after 24 hours at a concentration of said antibody of 100 nM by ADCC; has improved properties in antitumor therapy.
-
公开(公告)号：EP1836226B1
公开(公告)日：2011-06-22
申请号：EP06706157.2
申请日：2006-01-02
发明人： ENDL, Josef , FUENTES, Maria , GRAUS, Yvo , GROSSMANN, Adelbert , NEUMANN, Sebastian , PARREN, Paul , REBERS, Frank , REGULA, Joerg , SCHUMACHER, Ralf , SEEBER, Stefan , STRACKE, Jan , STUBENRAUCH, Kay-Gunnar , VAN DE WINKEL, Jan , VAN VUGT, Martine , VEREECKEN-VERPLOEGEN, Sandra
IPC分类号： C07K16/28 , A61K39/395 , A61P11/06 , A61P37/08 , C12N15/13 , C12N15/79 , C12N15/70 , C12N5/10 , C12N5/20 , C12N1/21
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： An antibody binding to IL-13Rαl, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
-
3.发明授权
公开(公告)号：EP1646720B1
公开(公告)日：2008-11-05
申请号：EP04763146.0
申请日：2004-07-09
发明人： GRAUS, Yvo , KOPETZKI, Erhard , KUENKELE, Klaus-Peter , MUNDIGL, Olaf , PARREN, Paul , REBERS, Frank , SCHUMACHER, Ralf , VAN DE WINKEL, Jan , VAN VUGT, Martine
IPC分类号： C12N15/13 , C12N5/16 , A61K39/395
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/2896 , C07K2317/73
-
4.发明公开
公开(公告)号：EP1646720A2
公开(公告)日：2006-04-19
申请号：EP04763146.0
申请日：2004-07-09
发明人： GRAUS, Yvo , KOPETZKI, Erhard , KUENKELE, Klaus-Peter , MUNDIGL, Olaf , PARREN, Paul , REBERS, Frank , SCHUMACHER, Ralf , VAN DE WINKEL, Jan , VAN VUGT, Martine
IPC分类号： C12N15/13 , C12N5/16 , A61K39/395
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/2896 , C07K2317/73
摘要： An antibody binding to IGF-IR and inhibiting the binding of IGF-I and IGF-II to IGF-IR which is characterized in that said antibody is a) is ofIgG1 isotype, b) shows a ratio of IC50 values of inhibition of the binding of IGF-I to IGF-IR to the inhibition of binding of IG-II to IGF-IR of 1:3 to 3:1, c) inhibits for at least 80% at a concentration of 5 nM IGF-IR phospohrylation in a cellular phosphorylation assay using 3T3 cells providing 400,000 to 600,000 molecules IGF-IR per cell in a medium containing 0.5% heat inactivated fetal calf serum (FCS) when compared to such an assay without said antibody, and d) shows no IGF-IR stimulating activity measured as IGF-IR phophorylation at a concentration of 10 µM in a cellular phosphorylation assay using 3T3 providing 400,000 to 600,000 molecules IGF-IR per cell in a medium containing 0,5% heat inactivated fetal calf serum (FCS) when compared to such an assay without said antibody has improved properties in antitumor therapy.
-
5.发明授权
公开(公告)号：EP1613658B1
公开(公告)日：2012-03-14
申请号：EP04725024.6
申请日：2004-04-01
发明人： GRAUS, Yvo , KOPETZKI, Erhard , KUENKELE, Klaus-Peter , MUNDIGL, Olaf , PARREN, Paul , REBERS, Frank , SCHUMACHER, Ralf , VAN DE WINKEL, Jan , VAN VUGT, Martine
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565
摘要： An antibody binding to IGF-IR and inhibiting the binding of IGF-I and IGF-II to IG-RI which is characterized in that said antibody is of human IgG1 isotype, and shows a ratio of inhibition of the binding of IGF-I to IGF-IR to the inhibition of binding of IGF-II to IGF-IR of 1:3 to 3:1, and induces celle death of 20% or more cells of a preparation of IGF-IR expressing cells after 24 hours at a concentration of said antibody of 100 nM by ADCC; has improved properties in antitumor therapy.
-
-
-
-
搜索结果
5 条记录 (耗时 0.019 秒)
